NEWS: 公告在東京證券交易所JASDAQ標準市場新上市

表紙
市場調查報告書

Nivolumab的中國市場:2021年∼2025年

Investigation Report on China's Nivolumab Market 2021-2025

出版商 China Research and Intelligence 商品編碼 1002607
出版日期 內容資訊 英文 50 Pages
商品交期: 最快1-2個工作天內
價格
Nivolumab的中國市場:2021年∼2025年 Investigation Report on China's Nivolumab Market 2021-2025
出版日期: 2021年04月23日內容資訊: 英文 50 Pages
簡介

中國的Nivolumab的銷售額,從2018年的990萬人民幣,到2020年增加到4,310萬人民幣。2020年的成長率是52.2%,不過,由於COVID-19流行,速度減低。中國的Nivolumab的銷售額的年複合成長率,2018年∼2020年是108.7%。

本報告提供中國的Nivolumab市場相關調查分析,COVID-19的影響,銷售額、銷售數量,價格,市場預測等相關的系統性資訊。

目錄

第1章 Nivolumab的相關概念

  • Nivolumab的適應症
  • 中國的Nivolumab的開發
  • 中國的Nivolumab的政府核准
  • COVID-19對中國的Nivolumab銷售的影響

第2章 中國的Nivolumab銷售

  • Nivolumab的銷售額
    • 整體銷售額
    • 銷售額:各地區
  • Nivolumab銷售數量
    • 本來銷售數量
    • 銷售數量:各地區
  • Nivolumab銷售:中國的各劑型
    • 注射
    • 其他劑型分析

第3章 中國的主要Nivolumab製造商分析

  • 主要的Nivolumab製造商市場佔有率分析
  • Bristol-Myers Squibb Pharma EEIG

第4章 中國的各種製造商Nivolumab的價格

  • Bristol-Myers Squibb Pharma EEIG (OPDIVO)

第5章 中國的Nivolumab醫藥品市場預測

  • 中國的Nivolumab市場發展的影響要素
  • 市場規模的預測
  • 市場趨勢的預測
目錄
Product Code: 2104475

Nivolumab is a human IgG4 monoclonal antibody that blocks PD-1, mainly used to treat non-small cell lung cancer, gastric or gastroesophageal junction adenocarcinoma, advanced renal cell carcinoma, and head and neck squamous cell carcinoma. Nivolumab was first developed by Medarex and Ono Pharmaceuticals. In 2009, Bristol-Myers Squibb acquired these two companies and obtained the patent for Nivolumab. Nivolumab was launched in China in 2018. By 2020, Bristol-Myers Squibb Pharma EEIG is the only manufacturer in the Chinese Nivolumab market.

According to CRI's market research, after Nivolumab entered the Chinese market, the sales value of Nivolumab in China increased from CNY9.9 million in 2018 to CNY 43.1 million in 2020. The growth rate in 2020 was 52.2%, which slowed down due to the COVID-19 epidemic. The CAGR of Nivolumab's sales values in China is 108.7 in 2018 to 2020%.

CRI analyzes that as the epidemic situation has been improved and the hospitals resume their operation, the sales of Nivolumab will have a recovery growth from 2021 to 2025. Besides, the sales will also increase due to market expansion. Currently, Nivolumab has three approved indications, including non-small cell lung cancer, head and neck squamous cell carcinoma, and gastric adenocarcinoma and gastroesophageal junction cancer. Its fourth indication application is at the approval stage. As the number of approved indications increases, the sales will continue to grow. On the other hand, the usage rate of Nivolumab was lower than that of other PD-1 products that have been included in the national medical insurance catalog. If the medical insurance negotiation for Nivolumab succeeds, the price adjustment can reduce the burden on patients, which will increase its usage rate.

Topics covered:

  • The impact of COVID-19 on China's Nivolumab market
  • Sales value and volume of China's Nivolumab 2016-2020
  • Competitive landscape of China's Nivolumab market
  • Prices of Nivolumab in China
  • Prices of Nivolumab in China by regions and manufacturers
  • Analysis on factors affecting the development of China's Nivolumab market
  • Prospect of China's Nivolumab market from 2021 to 2025

Table of Contents

1 Relevant Concepts of Nivolumab

  • 1.1 Indications for Nivolumab
  • 1.2 Development of Nivolumab in China
  • 1.3 Governmental Approval of Nivolumab in China
  • 1.4 The Impact of COVID-19 on Nivolumab sales in China

2 Sales of Nivolumab in China, 2018-2020

  • 2.1 Sales Value of Nivolumab
    • 2.1.1 Overall Sales Value
    • 2.1.2 Sales Value by Region
  • 2.2 Sales Volume of Nivolumab
    • 2.2.1 Overall Sales Volume
    • 2.2.2 Sales Volume by Region
  • 2.3 Sales of Nivolumab by Dosage Form in China, 2018-2020
    • 2.3.1 Injection
    • 2.3.2 Analysis of Other Dosage Forms

3 Analysis of Major Nivolumab Manufacturers in China, 2018-2020

  • 3.1 Analysis of Market Share of Major Nivolumab Manufacturers
    • 3.1.1 Investigation on Market Share by Sales Value
    • 3.1.2 Investigation on Market Share by Sales volume
  • 3.2 Bristol-Myers Squibb Pharma EEIG
    • 3.2.1 Enterprise Profile
    • 3.2.2 Sales of OPDIVO (BMS' Nivolumab) in China

4 Prices of Nivolumab for Different Manufacturers in China, 2020-2021

  • 4.1 Bristol-Myers Squibb Pharma EEIG (OPDIVO)

5 Prospect of Chinese Nivolumab drug Market, 2021-2025

  • 5.1 Influential Factors of Chinese Nivolumab Market Development
    • 5.1.1 The Impact of COVID-19 on Chinese Nivolumab Market
    • 5.1.2 Market Drivers and Opportunities
    • 5.1.3 Market Threats and Challenges
  • 5.2 Forecast on Market Size
  • 5.3 Forecast on Market Trend

List of Charts

  • Chart Patent Information About Nivolumab Injection Registration in China
  • Chart Sales Value of Nivolumab Injection over the World
  • Chart Sales Value of Nivolumab Injection in China, 2018-2020
  • Chart Sales Value of Nivolumab Injection in China by Regions, 2018-2020
  • Chart Sales Volume of Nivolumab Injection in China, 2018-2020
  • Chart Sales Volume of Nivolumab Injection in China by Regions, 2018-2020
  • Chart Market Share by Sales Value of Top Nivolumab Manufacturers in China, 2018-2020
  • Chart Sales Value and Volume of OPDIVO in China, 2018-2020
  • Chart Referential Prices of OPDIVO in China, 2020-2021
  • Chart Forecast on Sales Value of Nivolumab in China, 2021-2025
  • Chart Forecast on Sales Volume of Nivolumab in China, 2021-2025